TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05014776
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.
Study: NCT05014776
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
Study: NCT05014776
Drug: CRS-207
Normalized name: CRS-207
DrugBank: CRS-207 (DB17323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 \[1 × 10\^9 colony forming units (CFU) in 100ml NS\] will be administered IV on Day 2 of Cycles 1-6.
Study: NCT05946941
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04769908
Drug: Systemic Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
Study: NCT04769908
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib, 8mg or 12mg, po, QD
Study: NCT04769908
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab, IV, 200mg, q3w
Study: NCT06701396
Drug: Tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06015217
Drug: Cetaphil Healing Ointment
Normalized name: Petrolatum 71.5% Topical application Ointment [CETAPHIL HEALING OINTMENT]
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will use Cetaphil Healing Ointment on the diaper rash area with every diaper change
Study: NCT04975152
Drug: Cemiplimab-Rwlc
Normalized name: cemiplimab-rwlc
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Flat dose of cemiplimab-rwlc 350 mg IV every 3 weeks, up to 9 cycles.
Study: NCT06288373
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy administered concurrent with radiation therapy，cisplatin 40 mg/m2 IV once per week (QW) for 5 weeks
Study: NCT05062031
Drug: Atropine 0.05% eyedrops
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop each evening in both eyes for 24 months.
Study: NCT06315530
Drug: Telitacicept+SOC
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160mg once a week for 48 weeks
Study: NCT05734105
Drug: Ripretinib
Normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg tablets
Study: NCT05734105
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12.5 mg tablets
Study: NCT05384119
Drug: TTI-101
Normalized name: TTI-101
DrugBank: TTI-101 (DB17578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05384119
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral capsule
Study: NCT05384119
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablet
Study: NCT05384119
Drug: ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablet
Study: NCT04857671
Drug: Botulinum Toxin Type A in saline water
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 100 Allergan units Botulinum toxin A in a total of 2 ml sodium chloride (NaCl) 0,9% Braun.~5 IU of Botox per injection point (0,1ml); in total 100 IU per 20 injections points.
Study: NCT04857671
Drug: Isotone saline water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 20 injections points
Study: NCT04785651
Drug: Tibial osteotomy with Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure.
Study: NCT06537323
Drug: Femoral nerve block with0.25% bupivacaine guided by ultrasound.
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Femoral nerve block with0.25% bupivacaine guided by ultrasound.
Study: NCT06537323
Drug: PENG block with0.25% bupivacaine guided by ultrasound.
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PENG block with0.25% bupivacaine guided by ultrasound.
Study: NCT05661552
Drug: Evolocumab 140 MG/ML
Normalized name: evolocumab 140 MG/ML
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Randomly assigned Evolocumab + rosuvastatin + ezetimibe versus rosuvastatin + ezetimibe
Study: NCT05661552
Drug: Ezetimibe 10mg
Normalized name: EZETIMIBE 10MG TAB
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe 10mg will be assigned to all participants
Study: NCT05823363
Drug: Exparel with Bubivacaine
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10ml Exparel mixed with10ml bupivicaine in vaginal cuff
Study: NCT05823363
Drug: Bupivacaine only
Normalized name: Bupivacaine only product
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20ml of Bubivacaine in the vaginal cugg
Study: NCT06513104
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol will be administered orally.
Study: NCT04641273
Drug: Placebo for Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, intake orally.
Study: NCT04641273
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, intake orally. Starting dose 75 mg BID first week, increase to 150 mg BID in second week.
Study: NCT05303480
Drug: Chlormethine
Normalized name: Chlormethine
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlormethine gel 0.016%
Study: NCT05991284
Drug: Sacubitril-valsartan
Normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sacubitril-valsartan (target dose 97/103 mg twice daily)
Study: NCT04816162
Drug: ketofol
Normalized name: Ketozole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prepared in a ratio of (1:4) respectively), where 1ml of ketamine will be added to 20 ml of propofol in a syringe pump
Study: NCT04816162
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 ml (200 µg) of dexmedetomidine added to 0.9% normal saline in a syringe pump
Study: NCT04665700
Drug: BI 764198
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764198
Study: NCT06276283
Drug: DZD9008 plus Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DZD9008, 200 mg or 300 mg, once daily plus Bevacizumab 15 mg/kg, once every 3 weeks
Study: NCT05081583
Drug: Midazolam Hcl 1Mg/Ml Inj
Normalized name: MIDAZOLAM HCL 1MG/ML INJ
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mL of an intravenous solution (1 mg/mL) will be administered.
Study: NCT06033547
Drug: Cabotegravir Formulation F
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabotegravir Formulation F will be administered
Study: NCT06033547
Drug: Cabotegravir Formulation G
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabotegravir Formulation G will be administered
Study: NCT04624230
Drug: tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
Study: NCT05115110
Drug: Risdiplam
Normalized name: Risdiplam
DrugBank: Risdiplam (DB15305)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risdiplam will be administered orally once daily (QD) for the duration of the study.
Study: NCT05187182
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle
Study: NCT05004025
Drug: Opdivo
Normalized name: Opdivo
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Novacure Optune with Opdivo and Yervoy
Study: NCT05004025
Drug: Yervoy
Normalized name: Yervoy
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Novacure Optune with Opdivo and Yervoy
Study: NCT05260255
Drug: vitamin D2 ( calciferol )
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: add on vitamin D2( calciferol ) 40,000 IU/wk ( 2 cap) for 12 weeks
Study: NCT05800366
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human IgG1-bispecific antibody, via IV infusion
Study: NCT05800366
Drug: Polatuzumab
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion
Study: NCT05800366
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Per standard care, via IV infusion
Study: NCT05800366
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per standard care, orally
Study: NCT05753306
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via HIPEC
Study: NCT05753306
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via HIPEC
Study: NCT05753306
Drug: Hyperthermic Intraperitoneal Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo HIPEC
Study: NCT06549530
Drug: MVA-BN
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive 2 vaccinations of the same dose of MVA-BN vaccine 4 weeks apart (standard regimen).
Study: NCT05463731
Drug: Remternetug (IV)
Normalized name: Remternetug
DrugBank: Remternetug (DB18994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT05463731
Drug: Remternetug (SC)
Normalized name: Remternetug
DrugBank: Remternetug (DB18994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06029010
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Follow clinical administration.
Study: NCT05171647
Drug: Mosunetuzumab
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).
Study: NCT05171647
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).
Study: NCT05171647
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.
Study: NCT05171647
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Study: NCT05171647
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Study: NCT05171647
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Study: NCT06732505
Drug: [225Ac]Ac-DOTATATE
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose escalation phase will be divided into two cohorts: patients who had previously received 177Lu-PRRT will be enrolled in cohort 1, and patients who had not received 177Lu-PRRT will be enrolled in cohort 2. Dose escalation was performed independently in the two cohorts. DL1 will be administered as a dose of 90kBq/kg per cycle, and DL2 will be administered as a single dose of 120kBq/kg per cycle.Every patient will receive one \[225Ac\]Ac-DOTATATE infusion every 8 weeks for up to 4 cycles.
Study: NCT04093323
Drug: PD1 Inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04093323
Drug: Rintatolimod
Normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06291220
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous Infusion
Study: NCT06291220
Drug: ABBV-453
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT05721937
Drug: Abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: taken by mouth
Study: NCT06533527
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GLP1 medication
Study: NCT06533527
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLP1/GIP medication
Study: NCT06533527
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GLP1 medication
Study: NCT06533527
Drug: Dulaglutide
Normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GLP1 Medication
Study: NCT05969171
Drug: Sofantinib、abraxane、gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The combination of 3 weeks was a treatment cycle, and AG chemotherapy was defined as a maximum of 6 treatment cycles, and soantinib was continued until disease progression (PD, RECIST 1.1) or death (during patient treatment) or toxicity intolerance or other criteria for discontinuation of study therapy were met in the protocol.
Study: NCT05969171
Drug: Abraxane combined with gemcitabine
Normalized name: Abraxane
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abraxane combined with gemcitabine
Study: NCT06307678
Drug: Calcium Silicate
Normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium silicate based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length. At the second appointment, medicaments were removed, and second sampling was performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated.
Study: NCT06399757
Drug: APL-5125
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL-5125 is an oral drug (capsule) taken daily in 28-day cycles
Study: NCT05942001
Drug: HRS-5041
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-5041 was given oral administration, qd, at a 28-day cycle. Patients may continue to use HRS-5041 until disease progression or unacceptable toxicity occurs.
Study: NCT05327023
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC targeted dose based on busulfan test dose, with a default dose of 130 mg/m2/day, given as IV infusion over 3 hours each day for 4 days Transplant days -6 through day -3
Study: NCT05327023
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
Study: NCT05327023
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 IV infusion over 30-60 minutes once daily for 4 days Transplant days -6 through -3
Study: NCT05327023
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, maximum initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +70 with no taper. Doses should be modified as appropriate for drug interactions.
Study: NCT04973163
Drug: BI 1823911
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1823911
Study: NCT04973163
Drug: BI 1701963
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1701963
Study: NCT04973163
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm
Study: NCT06177028
Drug: Lenalidomide 10 mg
Normalized name: lenalidomide 10 MG
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide is a cancer drug, It is also known by it's brand name Revlimid.
Study: NCT04604691
Drug: Blinatumomab for Injection
Normalized name: Blinatumomab for Injection
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
Study: NCT05144334
Drug: BTX-1188
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
Study: NCT06479720
Drug: Combined pharmacotherapy with Solifenacin and Mirabegron
Normalized name: Mirabegron
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.
Study: NCT06479720
Drug: Solifenacin with vaginal estrogen cream
Normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
Study: NCT06479720
Drug: Mirabegron with vaginal estrogen cream
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
Study: NCT06412848
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is an observational study, participants who received avelumab as first line maintenance therapy after a PBCT.
Study: NCT05683548
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05683548
Drug: Pegylated interferon alpha2a
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05069428
Drug: Ramelteon 8mg
Normalized name: RAMELTEON 8MG TAB
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered crushed, orally at 20:30
Study: NCT06446830
Drug: multimodal analgesia and vitamin B
Normalized name: VITAMIN B
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B1, B6 , B9 , B12 in addition to the routine paracetamol and NSAID
Study: NCT06682572
Drug: Avutometinib (VS-6766) + Defactinib (VS-6063)
Normalized name: Avutometinib
DrugBank: Defactinib (DB12282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy
Study: NCT04433572
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
Study: NCT05630872
Drug: Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) 50 mg orally BID (\~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.